Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Author:

Moskowitz Craig H.1,Walewski Jan2,Nademanee Auayporn3,Masszi Tamas4,Agura Edward5,Holowiecki Jerzy6,Abidi Muneer H.7,Chen Andy I.8,Stiff Patrick9,Viviani Simonetta10,Bachanova Veronika11,Sureda Anna12,McClendon Teresa13,Lee Connie14,Lisano Julie13,Sweetenham John15

Affiliation:

1. Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL;

2. Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;

3. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;

4. 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary;

5. Blood and Marrow Transplantation, Baylor University Medical Center, Dallas, TX;

6. Department of Bone Marrow Transplantation & Oncohematology, Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland;

7. Bone Marrow Transplant Program, Spectrum Health Cancer Center, Michigan State University, Grand Rapids, MI;

8. Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR;

9. Cardinal Bernardain Cancer Center, Loyola University Medical Center, Maywood, IL;

10. Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

11. Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN;

12. Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d’Oncologia Hospitalet, Barcelona, Spain;

13. Seattle Genetics, Inc., Bothell, WA;

14. Takeda Oncology, Cambridge, MA; and

15. Department of Hematology and Blood and Marrow Transplant, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Abstract

Key Points Early consolidation with BV improves 5-year PFS vs best supportive care and reduces the need for subsequent therapy. At 5-year follow-up, BV shows long-term tolerability, with peripheral neuropathy continuing to improve and/or resolve.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference4 articles.

1. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant;Arai;Leuk Lymphoma,2013

2. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract];Horning;Ann Oncol,2008

3. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial;Moskowitz;Lancet,2015

4. European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man (appendix 1): methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137126.pdf. Accessed 29 January 2018.

Cited by 170 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3